Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × Anastrozole × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 63 Neoplasms 7 Neoplasm Metastasis 7 Breast Diseases 4 Neoplasms by Site 3 Carcinoma, Intraductal, Noninfiltrating 3 Ovarian Neoplasms 2 Endometrial Neoplasms 2 Breast Neoplasms, Male 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Diseases 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HER2-positive Breast Cancer 1 HER2 Negative Breast Cancer 1 Granulosa Cell Ovarian Cancer 1 Fallopian Tube Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Lobular 1 Carcinoma, Ductal, Breast 1 Breast Neoplasm Female 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Breast Cancer Female 1 Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡